Ferroptosis
抑制剂选择性比较
Ferroptosis产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7243 |
Ferrostatin-1 (Fer-1)Ferrostatin-1 (Fer-1)是一种有效的选择性的ferroptosis抑制剂，EC50为60 nM。 |
Indicated HCC cells were treated with sorafenib (5 µM) and erastin (10 µM) with or without cell death inhibitors (ferrostatin-1, 1 µM; liprostatin-1, 100nM; ZVAD-FMK,10 µM; necrosulfonamide, 0.5 µM) for 24 hours and cell viability was assayed (n=3, *p < 0.05 versus sorafenib or erastin treatment group).
|
|
| S7699 |
Liproxstatin-1Liproxstatin-1是一种有效的ferroptosis抑制剂，IC50为22 nM。 |
(a-d) Liproxstatin-1 treatment, given immediately after reperfusion, attenuated motor function decline measured by rotarod (a), progressive neurological deficits (b), n =8, final infarct volumes (c, right) and cognitive function decline (d). Representative TTC-stained serial brain sections 24 h after MCAO/reperfusion are shown in (c, left), scale bar=1 cm.
|
|
| S8792New |
UAMC-3203UAMC-3203是ferroptosis抑制剂，在IMR-32神经母细胞瘤细胞中IC50为10 nM。 |
||
| S7242 |
ErastinErastin是一种ferroptosis激活剂，通过作用于线粒体VDAC而起作用，选择性作用于携带致癌基因RAS的肿瘤细胞。 |
PANC1 and PANC2.03 cells were treated with staurosporine or erastin (D) in the absence or presence of indicated cell death inhibitors for 24 hours. Cell viability was assayed (n = 3, *P < 0.05).
|
|
| S8254 |
FIN56FIN56是ferroptosis的特异性诱导剂。 |
||
| S8155 |
RSL3RSL3是一种ferroptosis的激活剂，不依赖于VDAC，对携带致瘤性RAS的肿瘤细胞具有选择性。它结合并使GPX4失活，介导GPX4所调节的铁死亡。 |
Fluvastatin treatment of HT-1080 cells decreases GPX4 protein levels in a time- and concentration-dependent manner and synergized with co-treatment with the direct GPX4 inhibitor RSL3.
|
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7243 |
Ferrostatin-1 (Fer-1)Ferrostatin-1 (Fer-1)是一种有效的选择性的ferroptosis抑制剂，EC50为60 nM。 |
Indicated HCC cells were treated with sorafenib (5 µM) and erastin (10 µM) with or without cell death inhibitors (ferrostatin-1, 1 µM; liprostatin-1, 100nM; ZVAD-FMK,10 µM; necrosulfonamide, 0.5 µM) for 24 hours and cell viability was assayed (n=3, *p < 0.05 versus sorafenib or erastin treatment group).
|
|
| S7699 |
Liproxstatin-1Liproxstatin-1是一种有效的ferroptosis抑制剂，IC50为22 nM。 |
(a-d) Liproxstatin-1 treatment, given immediately after reperfusion, attenuated motor function decline measured by rotarod (a), progressive neurological deficits (b), n =8, final infarct volumes (c, right) and cognitive function decline (d). Representative TTC-stained serial brain sections 24 h after MCAO/reperfusion are shown in (c, left), scale bar=1 cm.
|
|
| S8792New |
UAMC-3203UAMC-3203是ferroptosis抑制剂，在IMR-32神经母细胞瘤细胞中IC50为10 nM。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7242 |
ErastinErastin是一种ferroptosis激活剂，通过作用于线粒体VDAC而起作用，选择性作用于携带致癌基因RAS的肿瘤细胞。 |
PANC1 and PANC2.03 cells were treated with staurosporine or erastin (D) in the absence or presence of indicated cell death inhibitors for 24 hours. Cell viability was assayed (n = 3, *P < 0.05).
|
|
| S8254 |
FIN56FIN56是ferroptosis的特异性诱导剂。 |
||
| S8155 |
RSL3RSL3是一种ferroptosis的激活剂，不依赖于VDAC，对携带致瘤性RAS的肿瘤细胞具有选择性。它结合并使GPX4失活，介导GPX4所调节的铁死亡。 |
Fluvastatin treatment of HT-1080 cells decreases GPX4 protein levels in a time- and concentration-dependent manner and synergized with co-treatment with the direct GPX4 inhibitor RSL3.
|
